AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06379074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information on pregnancy-related issues
Description: Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions.
Study NCT05229068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
Study NCT04999163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortix System
Description: Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
Study NCT04715074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews
Description: We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
Study NCT04715074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot
Description: Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
Study NCT05105594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey application
Description: Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
Study NCT06241170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesentery-guided resection margin
Description: The research team positions the proximal margin of the anastomosis in a way that the mesentery reaches the point of being palpable and where the fat appears entirely normal under direct visual observation, in contrast to the mesentery near the proximal and distal ends of the anastomosis.
Study NCT05159375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elio
Description: Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
Study NCT05159375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SMCC
Description: Placebo comparator
Study NCT05657561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Mobilization training was given to the intervention group.
Study NCT05875896 — intervention group
Intervention type: PROCEDURE
Intervention: Total wrist fusion
Description: Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
Study NCT05263089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)
Description: Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s.
Study NCT05263089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESTELITE® Alpha; Tokuyama, Tokyo, Japan
Description: The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
Study NCT06067555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
Study NCT05904665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA methylation dynamic monitoring
Description: ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
Study NCT05125770 — intervention group
Intervention type: BIOLOGICAL
Intervention: New crown vaccine
Description: New Coronavirus vaccine
Study NCT06067555 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
Study NCT06067555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL
Study NCT06067555 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® Quadrivalent
Description: Intramuscular injection of 0.3mL
Study NCT06067555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic Saline
Description: Intradermal injection of 0.3mL (control)
Study NCT06052696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 Suspension for Injection
Description: After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Study NCT06052696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Study NCT03037814 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Amalgam
Description: Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
Study NCT06475755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy combined with antiangiogenic
Description: neoadjuvant： Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
Study NCT06475755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immunochemotherapy
Description: neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
Study NCT05225623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWLT
Description: This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
Study NCT05225623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control for BWLT
Description: This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
Study NCT04914793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescribing guideline mobile phone application (MicroGuide)
Description: This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
Study NCT05025332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Study NCT05125848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
Study NCT06248372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
Study NCT06248372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
Study NCT04888390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muti-model exercise intervention
Description: The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
Study NCT06383897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10398
Description: SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
Study NCT06383897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10398 Placebo
Description: SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
Study NCT04888390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease and exercise suggestion
Description: The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
Study NCT05119894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 1
Description: Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
Study NCT05119894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 2
Description: Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
Study NCT05119894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 3
Description: Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
Study NCT04684537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Description: The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.
Study NCT04684537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided piriformis steroid injection
Description: all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.
Study NCT05119894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 4
Description: Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
Study NCT06364800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
Study NCT06364800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 monoclonal antibody
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study NCT06364800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study NCT06364800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: targeted drugs
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Study NCT06364800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted drugs
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Study NCT04875234 — intervention group
Intervention type: DEVICE
Intervention: Clear-K Low Vision Aid Treatment
Description: A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
Study NCT05603468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
Study NCT05603468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
Study NCT05603468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT05402280 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep protocol
Description: To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
Study NCT05847426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of standard audiological + fNIRS test results
Description: Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
Study NCT05847426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provision of standard audiological test results only
Description: The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
Study NCT05134181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacroiliac joint injection
Description: Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied
Study NCT06482866 — intervention group
Intervention type: OTHER
Intervention: Cottle's septoplasty and radiocoagulation conchoplasty
Description: Cottle's septoplasty and radiocoagulation conchoplasty Study group - added nasal splits; Control group - nasal splits weren't used.
Study NCT04618874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid on-site evaluation
Description: Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
Study NCT06490107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab combined with S-1
Description: The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles
Study NCT05031364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interventions for Anxiety in Children with Autism (BIACA)
Description: In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
Study NCT05031364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)
Description: Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
Study NCT06195982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketone ester
Description: 500 mg/kg of ketone ester administered approximately 1 hour prior to the maximal exercise testing and 250 mg/kg administered approximately 30 minutes prior to submaximal exercise testing
Study NCT06195982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ketone-free placebo administered approximately 1 hour prior to the maximal exercise testing and ketone-free placebo administered approximately 30 minutes prior to submaximal exercise testing
Study NCT05662033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: AZD6793 will be administered orally
Study NCT05662033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally